The antihypertensive efficacy and tolerability profiles of the selective AT 1 receptor antagonists telmisartan and losartan were compared with placebo in a 6-week, multinational, multicentre, randomised, double-blind, double-dummy, parallel-group study of 223 patients with mild-to-moderate hypertension, defined as clinic diastolic blood pressure (DBP) у у у95 and р р р114 mm Hg, clinic systolic blood pressure (SBP) у у у140 and р р р200 mm Hg, and 24-h ambulatory DBP у85 mm Hg. After a 4-week single-blind placebo run-in, eligible patients were randomised to receive telmisartan 40 mg, telmisartan 80 mg, losartan 50 mg, or placebo. Ambulatory blood pressure monitoring (ABPM) after 6 weeks of double-blind therapy showed that all active treatments produced significant (P Ͻ Ͻ Ͻ 0.01) reductions from baseline in 24-h mean SBP and DBP compared with placebo. During the 18-to-24 h period after dosing, the reductions in SBP/DBP with telmisartan 40 mg
Introduction
The renin-angiotensin system (RAS) is an important regulator of blood pressure and extracellular fluid volume, particularly for patients with hypertension. It is widely recognised that angiotensin II (AII) is the primary effector hormone of the RAS and that this peptide initiates acute pressor effects and chronic cell growth antecedent to the development of cardiac hypertrophy and glomerulosclerosis. 1, 2 Although blockade of the RAS by angiotensinconverting enzyme (ACE) inhibitors is a logical approach to the treatment of hypertension, it has significant limitations. ACE inhibitors are non-specific in their effects, preventing the conversion of angio- tensin I to AII, but also affecting other biologically important peptides, including bradykinin. Elevation in bradykinin levels secondary to ACE inhibitor therapy is believed to induce microvascular leakage in airways, allowing the penetration of substance P into airways tissues and the subsequent development of dry, persistent cough. [3] [4] [5] Moreover, ACE inhibitors only block the formation of AII generated in the RAS. It is now known, however, that AII can be formed in local tissue, such as the heart, by pathways independent of ACE. 6, 7 Because of these limitations, recent drug-discovery research has focused on the development of agents that specifically inhibit a particular AII receptor subtype, AT 1 , which is responsible for all the known physiologic actions of AII relevant to cardiovascular homeostasis. 8 Telmisartan, a new, orally active, non-peptide AII receptor antagonist, displays potent and selective AT 1 receptor blockade in vivo. 9 In non-clinical studies, telmisartan dose-dependently blocked the pressor effects of AII and decreased mean arterial blood pressure in spontaneously hypertensive rats. 10 With its pharmacokinetic profile that includes rapid absorption (t max 0.5 to 2 h) and a prolonged half-life (about 24 h), telmisartan may offer a beneficial efficacy and tolerability profile. Published data on the use of telmisartan in humans confirms its sustained 24-h antihypertensive effects 11, 12 and clinical efficacy in comparison with enalapril in patients with mild-to-moderate hypertension. 13 Ambulatory blood pressure monitoring (ABPM) is becoming the method of choice in evaluating the efficacy of new antihypertensive agents and assessing the adequacy of treatment, since it overcomes some of the problems encountered with office cuff measurements, such as wide blood pressure variability and measurement errors. 14, 15 Therefore, in this study, ABPM was used in addition to cuff measurements to determine efficacy.
The aim of this study was to compare the efficacy and tolerability of telmisartan with losartan, the first marketed AT 1 antagonist, versus placebo in patients with mild-to-moderate hypertension, focusing on the 18-to-24-h period after dosing, a period when any differences in antihypertensive therapy might be most apparent.
Patients and methods

Selection of patients
Men and women between 18 and 75 years of age with mild-to-moderate hypertension, defined as diastolic blood pressure (DBP) у95 mm Hg and р114 mm Hg and systolic blood pressure (SBP) у140 mm Hg and р200 mm Hg, with a mean 24-h ambulatory DBP у85 mm Hg at baseline were included.
Excluded were women of child-bearing potential, patients with known or suspected secondary hypertension, hepatic or renal disease, cardiovascular disease or arrhythmias, uncontrolled or insulindependent diabetes mellitus, sodium depletion, hyperkalaemia, chronic use of oral anticoagulants, digoxin, or salt substitutes containing potassium chloride, use of short-acting nitrates or lithium, neuroleptics, or antidepressants, unstable high doses of NSAIDs or aspirin, or anyone receiving any investigational therapy within 1 month before the study. Patients receiving more than two antihypertensive medications at screening were also excluded as they were considered more likely to have severe hypertension.
Written informed consent was obtained from each patient, and the study was approved by the Institutional Review Board at each centre and conducted in accordance with the Declaration of Helsinki.
Study design
This 6-week, multinational, multicentre, randomised, double-blind, double-dummy, placebo-controlled, parallel-group study compared the blood pressure reduction profiles and tolerability of telmisartan 40 mg and 80 mg with losartan 50 mg in patients with mild-to-moderate hypertension. The study was divided into two periods: placebo run-in and a 6-week double-blind treatment period.
Placebo run-in: Initial screening and withdrawal of antihypertensive medication was followed by a 4-week placebo run-in phase. For eligible patients, antihypertensive medications were discontinued and placebo medication was dispensed. Patients were instructed to take their medication at the same time (between 7.00 and 10.00 am) each day. The final visit of this phase was scheduled to take place 4 weeks later, and patients were requested to come to the clinic 23 h after taking their medication and not to drink products containing caffeine or to smoke or exercise before their clinic visit. At the end of this period, baseline assessments, including medical history, physical examination, 12-lead ECG, laboratory evaluations, supine and standing cuff blood pressures and heart rates, and ambulatory blood pressure monitoring (ABPM) were performed. Adverse events and any concomitant medication changes were also noted at this time. Patients were permitted to continue into the double-blind phase of the study if supine trough mean DBP was у95 mm Hg and р114 mm Hg and supine trough mean SBP was у140 mm Hg and р200 mm Hg with compliance Ͼ80% for the entire run-in period and at least 100% for the last 3 days of this run-in phase. Eligible patients were fitted with an ABP monitor and were randomised to one of four parallel, oncedaily treatment groups: telmisartan 40 mg, telmisartan 80 mg, losartan 50 mg, or placebo. The mean diastolic ABP for each patient had to be у85 mm Hg for the recording period (24 or 36 h).
Double-blind treatment:
During this 6-week period, patients were instructed to take study drug once daily with water at approximately the same time every day. A double-dummy trial design was used as the trial medication was provided in tablets of differing sizes and shapes. Thus, patients took active treatment and placebos matching either telmisartan 40 mg or 80 mg or losartan 50 mg. Patients returned to the clinic twice during this period: once between active treatment on days 14 and 21, and again at day 42 (6 weeks). At each visit, a physical examination and laboratory tests were completed and cuff blood pressures and pulse rate were evaluated.
Observation Methods
ABPM:
On the first and last visits, between 7.00 am and 10.00 pm on a weekday of normal activity, and after cuff blood pressure had been measured, eligible patients were fitted with an ABP monitor (Spacelabs 90207: SpaceLabs, Inc, Redmond, WA, USA), which measured blood pressure every 15 min. The total duration of the ABPM recording was 24 h.
Cuff blood pressure and heart rate measurements: During all clinic visits, standing and sitting heart rate and supine and standing blood pressures were measured using a mercury sphygmoman-ometer as follows. After the patient had been in a supine position for 5 min, three consecutive systolic and diastolic measurements (Korotkoff Phase V) were taken 2 min apart. Three additional measurements were taken at 2-min intervals with the patient in the standing position. The blood pressure measurements recorded were the means of the three measurements. Supine heart rate was taken during the 2-min interval between the second and third blood pressure reading. Standing heart rate was measured immediately after standing blood pressure readings were taken.
Efficacy
The primary efficacy parameter was the change from baseline in ABPM-derived mean SBP and DBP after final dosing over the 18 to 24-h postdose interval for patients receiving telmisartan (40 mg or 80 mg), losartan 50 mg, and placebo. The primary population analysed for this end-point included all patients randomised who received at least one dose of study medication and who had a valid baseline and post-treatment ABPM.
Secondary study objectives included a comparison of the change from baseline in mean 24-h ABPM-derived SBP and DBP after final dosing. The 24-h mean ABPM was defined as the average of the hourly mean ABPM values for 24 h. Also, comparisons of blood pressure reduction during various prespecified periods of the day were explored. Daytime was defined as the period from 6.00 am to 10.00 pm; night-time from 10.01 pm to 5.59 am; and morning was defined as 6.00 am to 11.59 am.
Additionally, the efficacy of antihypertensive treatment was evaluated by comparing differences in mean clinic SBP and DBP assessed by standard sphygmomanometer from baseline to final visit.
Therapeutic SBP and DBP responses (defined, respectively, as a reduction from baseline of у10 mm Hg in trough supine cuff SBP, and a trough supine cuff DBP Ͻ90 mm Hg or reduction from baseline of у10 mm Hg in trough supine cuff DBP) and normalisation (ABPM 24-h mean DBP Ͻ85 mm Hg and SBP Ͻ135 mm Hg) rates at week 6 were also assessed.
To be valid, an ABP monitor had to span more than 24 h, have missing no more than two non-consecutive, hourly means and contain at least 48 valid measurements during the 24-h period. To be considered evaluable, patient compliance with treatment had to be Ͼ80% for the entire double-blind phase and у100% for the last 3 days of this phase.
Safety and tolerability
Safety was evaluated based on the incidence of adverse events and changes from baseline detected during physical examinations, laboratory tests, and 12-lead ECGs. All patients who received at least one dose of study medication were included in the safety analyses.
Physical examinations, including supine and standing blood pressure, heart rate, weight, height, waist and hip measurements, were performed at baseline and at the end of the trial or upon premature withdrawal. A 12-lead resting ECG was recorded for each patient at visits 2 and 4. Blood and urine samples were taken for laboratory analysis at baseline and at the end of treatment or upon premature withdrawal.
All adverse events observed by the investigator or mentioned voluntarily by the patient were documented as to type, onset, duration, severity, treatment outcome, and relation to study medication. Serious adverse events included death, life-threatening events, or any event that caused disability or required prolonged hospitalisation.
Statistics
Changes from baseline in the 18 to 24-h ABPM mean by treatment group were compared using an analysis of covariance (ANCOVA) model, with baseline 18 to 24-h blood pressure as the covariate, country as a stratification variable and treatment. Tests between treatments were accomplished by applying the Dunnett-Tamhane multiple step-wise procedure. 16, 17 Secondary ABPM end-points were also evaluated using a similar approach. Rates were evaluated using the Cochran-Mantel-Haenszel method stratified by country.
Results
Patient disposition
Two-hundred and twenty-three (223) patients entered the double-blind period of this trial, and were randomised to receive telmisartan 40 mg (n = 57), telmisartan 80 mg (n = 54), losartan 50 mg (n = 57), or placebo (n = 55). This comprised the safety population. One patient was lost to follow-up without any data. The 222 patients with baseline and follow-up cuff data comprised the intent-to-treat (ITT) population. Of these, 15 patients were excluded from the evaluable data set, 11 having no final ABPM measurement, three (two in the telmisartan 40-mg group and one in the telmisartan 80-mg group) because of protocol violations (ie, improper dosing time relative to ABPM or insufficient readings on ambulatory BP monitors) and one with an invalid ABPM, leaving 207 evaluable patients for ABPM analysis. Thirteen patients discontinued treatment prematurely: seven due to adverse events (five in the losartan group; one each in the telmisartan 40-mg and placebo groups); three for lack of efficacy (two in the losartan group and one in the placebo group); and two withdrew consent (one each in the telmisartan 40-mg and placebo groups).
Patient demographics
There were no relevant differences between the treatment groups for any demographic variables (Table 1) . Baseline cuff blood pressures, supine and standing heart rates ( Table 2) , physical examination and ECG findings were comparable; however, the 24-h ambulatory BP means of losartan and placebo patients were somewhat lower than those of tel- misartan patients. Therefore, analyses of ABPM responses were adjusted for baseline differences.
ABPM
By ABPM, telmisartan 40 mg and 80 mg produced significantly greater reductions from baseline than losartan in mean 18 to 24-h and mean 24-h SBP and DBP after final dosing (Table 3) . Compared with placebo, ABPM data showed that all active treatments produced significant reductions in mean 24-h SBP and DBP. During the day, night, and morning monitoring periods, telmisartan 40 mg and 80 mg induced significant reductions from baseline compared with placebo in both SBP and DBP. Significant reductions were also seen for losartan 50 mg during these periods (Table 4) . Compared with losartan, telmisartan 80 mg produced significantly greater reductions for both SBP and DBP during all evaluation periods. Telmisartan 40 mg produced significantly greater reductions than losartan 50 mg for both SBP and DBP in the night-time period, and for DBP in the morning period. Although losartan produced significant 24-h mean changes in SBP and DBP after final dosing, the reductions detected during the 18 to 24-h postdose period were not statistically different from placebo (Table 3) . Twenty-four hour ABPM plots for change from baseline in DBP ( Figure 1 ) and SBP ( Figure 2 ) show clear separations in the blood pressure lowering efficacies of the active treatment groups from that of the placebo group. 
Cuff blood pressure measurements
Clinic trough SBP and DBP were significantly decreased from baseline for both telmisartan 40 mg (14.2/8.6 mm Hg) and 80 mg (15.9/9.7 mm Hg) in comparison with placebo (4.8/3.5 mm Hg), while losartan induced significant decreases in SBP (10.3 mm Hg), but not for DBP (6.0 mm Hg), in comparison with placebo. Moreover, decreases in clinic trough supine SBP and DBP from baseline to the final clinic visit were significantly greater with telmisartan 80 mg than with losartan 50 mg (Table 3) .
Therapeutic response and normalisation rate
During week 6, the percentage of patients with clinic cuff blood pressure response for SBP/DBP was 69.8%/52.8% for telmisartan 80 mg, 56.1%/40.4% for telmisartan 40 mg, 45.6%/29.8% for losartan 50 mg, and 23.6%/20.0% for placebo. Both the diastolic and systolic response rates for telmisartan 80 mg were significantly greater than for placebo and losartan, while telmisartan 40 mg produced systolic and diastolic rates that were significantly different from placebo but not losartan. The systolic response rate for losartan was significantly different from placebo, but the diastolic response rate was not. The percentage of patients whose ambulatory blood pressure had been normalised by week 6 was significantly greater than placebo (7.5%) for all active treatments (46.2% for telmisartan 80 mg, 32.7% for telmisartan 40 mg, and 28% for losartan 50 mg). Although a numerical trend in normalisation rates was apparent among the active treatments, the differences between telmisartan (40 or 80 mg) and losartan rates did not achieve statistical significance.
Safety and tolerability
The overall incidence of adverse events during the 6 weeks of active treatment was comparable among all groups, except for headache, which occurred more frequently in the placebo group. One patient (1.8%) treated with telmisartan 40 mg, five patients (8.8%) treated with losartan 50 mg, and one placebo patient (1.8%) withdrew from the study due to an adverse event. No serious treatment-related adverse events were reported, and only one event of severe intensity (headache reported by a patient receiving losartan 50 mg) was reported. The most frequently reported adverse events were headache, upper respiratory tract infection, dizziness, fatigue, pain, and bronchitis. Most adverse events were considered mild-to-moderate in intensity and were unrelated to study medication.
No clinically relevant changes from baseline were observed in heart rate or in laboratory parameters. Rebound hypertension was not observed in any of the study subjects.
Discussion
This randomised, 6-week, double-blind study compared the antihypertensive efficacy of telmisartan 40 mg or 80 mg and losartan at the usual reference dose of 50 mg using ABPM. The use of ABPM has certain advantages over isolated cuff measurements in assessing the efficacy of antihypertensive treatments. First, ABPM overcomes the potential for 'white coat' hypertension, evident in clinic cuff recordings. 18 Second, the large number of measurements between successive doses with ABPM permits an accurate evaluation of any meaningful changes in blood pressure between the typical time of maximal effect (during the first few hours after dosing) and minimal effect (just before the next scheduled once-daily dose). 19 Third, comparisons between various time intervals during the 24-h postdose period permit an overall evaluation of the antihypertensive consistency of a particular agent. Finally, ABPM measurements can be used to examine blood pressure at times inaccessible or inconvenient for obtaining cuff clinic readings, such as the early morning period shortly after the patient arises. This is important because blood pressure increases during this period have been associated with increases in ventricular mass 20 and a greater incidence of cardiovascular morbidity. 21, 22 All three active treatments (telmisartan 40 mg and 80 mg and losartan 50 mg) significantly lowered mean hourly blood pressure and blood pressure during the day and night periods compared with placebo, determined by ABPM. Plotting change from baseline in DBP and SBP in Figures 1 and 2 removes the normal diurnal variation from the plots, but the plots are considered more appropriate than traditional blood pressure profile plots because they are visually consistent with the primary efficacy end-point findings. For telmisartan, but not losartan, significant decreases in blood pressure compared with placebo were seen at the end of the 24-h dosing interval (18-24 h postdose). The principal findings of this study, however, demonstrated that, compared with losartan 50 mg, telmisartan 40 mg and 80 mg were significantly more effective in lowering SBP and DBP during the 18 to 24-h postdose period, as measured by ABPM. The antihypertensive actions of losartan 50 mg, in the present study, appeared similar to those observed in previous clinical studies, [23] [24] [25] although few have used ABPM. Nevertheless, the results of our study show that telmisartan is more effective than losartan during the 18 to 24-h period postdose.
ABPM does have limitations that are difficult to address in clinical trials. Variations in an individual's activity level during the day may lead to marked variations in blood pressure that are unrelated to treatment. [26] [27] [28] These variations, in addition to blood pressure variations secondary to the circadian rhythm, may explain the lack of reproducibility sometimes noted for results obtained using ABPM. 29, 30 ABPM that includes a shorter period of evaluation (eg, 22 to 24-h postdose) may prevent these problems. However, typically, the accuracy of evaluating blood pressure changes in response to treatment is inversely related to the length of the evaluation period. 31, 32 None of the limitations inherent in the ABPM technique can adequately explain the differences in efficacy between telmisartan and losartan observed in this study, since they were evident during all ABPM evaluation periods.
There is some evidence that losartan administered twice daily shows improved efficacy over once-daily losartan, and in certain countries losartan is approved for once-or twice-daily administration. This trial was designed to compare once-daily dosing of telmisartan and losartan, and the blinding of the study was enhanced by this matching of drug regimens. ABPM measurements, by allowing for the study of time periods not covered by office visit cuff measurements, provide additional, valuable information. To the best of our knowledge, there have been few studies of losartan utilizing ABPM measurements. Such studies contain small numbers of patients and have most often been limited to an evaluation of an entire 24-h time period, ie no information is available on shorter periods, and in particular, the 18 to 24-h time period chosen in this study.
The more consistent blood pressure control seen with once-daily telmisartan versus losartan in this study may be attributable to differences in pharmacokinetics. A prolonged half-life has been linked to duration of clinical action for certain antihypertensive agents. 33 Telmisartan displays a prolonged halflife of about 24 h, while in contrast, the half-life of the active losartan metabolite, E-3174, is 6 to 9 h. 34 An alternative explanation might be that the dose of losartan selected was too low. However, work by Gradman et al 35 suggests that there is little, if any benefit in additional blood pressure reduction achieved by increasing the dose of losartan above 50 mg once daily. In this study, all treatments were well tolerated and no difference in the incidence of side effects was noted among groups.
In conclusion, telmisartan at doses of 40 mg and 80 mg once daily was effective and well tolerated in the treatment of mild-to-moderate hypertension. In this study, telmisartan provided sustained 24-h blood pressure control and may offer advantages over losartan 50 mg once daily in terms of blood pressure reductions, particularly over the 18 to 24-h postdose period.
